Syndicated P&T Session: Atopic Dermatitis
MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
Learn how you can use P&T Perspectives to:
- Gain an understanding of the impact of these agents in atopic dermatitis and how that might impact your brand
- Boost your brand by identifying the key differentiators and any unforeseen access barriers
- And more
Interested in obtaining the full video and learning more about how you can take advantage of P&T Perspectives?